Tokyo, Oct. 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059271) titled 'IMBRUVICA Capsules 140mg Specified drug-use survey in patients with WM/LPL' on Oct. 2.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - primary Waldenstrom's macroglobulinemia / lymphoplasmacytic lymphoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To examine the safety of IMBRUVICA Capsules 140 mg (Hereinafter referred to as this drug) in patients with primary Waldenstrom's macroglobulinemia / lymphoplasmacytic lymphoma (WM/LPL) treated for the first time in clinical practice.
Basic objectives2 - Saf...